The main purpose of this study is to learn about the side effects of LY3437943 when given to Japanese participants with type 2 diabetes mellitus. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3437943 or placebo given just under the skin. For each participant, the study will last up to 5 months, inclusive of screening and will include 16 visits to the study center.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
64
Medical Corporation Heishinkai OCROM Clinic
Suita-shi, Osaka, Japan
P-one clinic
Hachiōji, Tokyo, Japan
Clinical Research Hospital Tokyo
Shinjuku-ku, Tokyo, Japan
Yokohama Minoru Clinic
Yokohama, Japan
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Baseline through Day 106
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3437943
PK: Cmax of LY3437943
Time frame: Predose on Day 1 through Day 81
PK: Area Under the Concentration Versus Time Curve (AUC) of LY3437943
PK: AUC of LY3437943
Time frame: Predose on Day 1 through Day 81
Change from Baseline in Mean Daily Plasma Glucose (PG)
Change from baseline in mean daily PG from 6-point PG profile
Time frame: Baseline through Day 80
Change from Baseline in Glycated Hemoglobin (HbA1c)
Change from Baseline in HbA1c
Time frame: Baseline through Day 78
Change from Baseline in Fasting Glucose
Change from Baseline in Fasting Glucose
Time frame: Baseline through Day 78
Change from Baseline in Body Weight
Change from Baseline in Body Weight
Time frame: Baseline through Day 78
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.